Devyser Diagnostics AB (publ) (the "Company" or the "Group") announces that its preliminary sales for the second quarter of 2026 are weaker than indicated by the information and conditions available at the beginning of the quarter. During the second quarter of 2026, the Group's preliminary net sales amounted to SEK 60.2 million. For the first half of the year, preliminary net sales amounted to SEK 122.0 million, in line with the same period last year.
Sales during the second quarter were negatively impacted by inventory build-up at the Company's largest distributor during 2025 and the beginning of 2026, which reduced the distributor's purchasing needs during the period.
The Group's direct markets and other distributor markets continued to deliver positive sales growth.
As a result of the distributor's inventory build-up, Devyser expects sales to this distributor to continue at a softer growth rate for the remainder of the current year. From 2027 onwards, sales to the distributor are expected to normalize. The Company views the future development of the business and its growth prospects with confidence.
Despite the weaker sales performance during the period, the Company assesses that the Group's liquidity and cash flow forecast remain satisfactory. Cash flow and operating expenses continue to be closely monitored.
The financial information presented above is preliminary. The Company will publish its complete interim report for the second quarter of 2026, including comments on the development during the period, on Monday, July 20, 2026, at 07:30 CEST. A webcast conference call regarding the interim report will be held on the same day at 09:00 CEST.
For more information, please contact:
Jan Wahlström, CEO
Email: ir@devyser.com
Telephone: +46 8 562 158 50
About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.?
Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.?
We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.?
Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.?
Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.
Discover how we're shaping the future of lab diagnostics at www.devyser.com.?
This information is information that Devyser Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-02 20:50 CEST.
